Medicine

Grants

Grants per year 1991 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2034

• 1305 Active
• 5997 Finished

Grants per year

Search results

• Active

  Evaluating and Validating Cardiovascular Risk Prediction Equations Across All Race and Ethnicities

  Khan, S. S. (PD/PI) & Huang, X. (Co-Investigator)

  American Heart Association

  4/1/24 → 3/31/25

  Project: Research project

• Prot #12.06.2022: Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples for the Non-Endoscopic Detection of Barrett’s Esophagus with and without Dysplasia

  Komanduri, S. (PD/PI)

  Mayo Clinic, EXACT Sciences Corporation

  3/28/24 → 3/28/27

  Project: Research project

• Prot #IM0271015: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis (PPF)

  Tomic, R. (PD/PI)

  Fortrea, Inc., Bristol-Myers Squibb Company

  3/26/24 → 3/26/27

  Project: Research project

• Modulation of Lung Immune Responses to Viral Infection - Project 2

  Williams, A. J. (PD/PI), Fourati, S. (Other) & Zhang, L. (Other)

  Jackson Laboratory, National Institute of Allergy and Infectious Diseases

  3/21/24 → 2/28/29

  Project: Research project

• Project 3 Tech/Dev - Modulation of Lung Immune Responses to Viral Infection

  Williams, A. J. (PD/PI)

  Jackson Laboratory, National Institute of Allergy and Infectious Diseases

  3/21/24 → 2/28/29

  Project: Research project

• Prot #CYTB323J12201: A Phase 2, Adaptive, Randomized, Open-Label, Assessor-Blinded Active-Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Standard of Care in Patients Suffering from Systemic Lupus Erythematosus (SL

  Georges, G. E. (PD/PI)

  Novartis Pharmaceuticals Corporation

  3/19/24 → 12/31/30

  Project: Research project

• Prot #STU00204868-MOD0146: Validation of a Host-Protein Based Assay to Distinguish Between Viral and Bacterial Infection in Critically Ill Patients with CommunityAcquired Pneumonia: A Cohort Study

  Pickens, C. I. (PD/PI) & Wunderink, R. G. (Co-Investigator)

  DiaSorin Inc.

  3/18/24 → 3/18/27

  Project: Research project

• Prot #1438-0007: DAREON™-7: A Phase I, Open-Label, Dose Escalation and Expansion Trial to Investigate Safety and Tolerability of BI 764532 Intravenous Infusions in Combination with Standard of Care (Platinum and Etoposide) in First-Line Treatment of Patie

  Benson III, A. B. (PD/PI)

  Boehringer Ingelheim Pharmaceuticals, Inc.

  3/16/24 → 3/16/27

  Project: Research project

• Prot #IMM1104-101: A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants with Previously Treated RAS-Mutated Advanced or Metastatic Solid Tumors

  Chandra, S. (PD/PI)

  Tempus Compass, LLC, Immuneering Corporation

  3/15/24 → 3/15/27

  Project: Research project

• Prot #CIP-002: PreVail-PH2 Study: Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients with Pulmonary Hypertension (Group 2)

  Schimmel, D. R. (PD/PI)

  Gradient Denervation Technologies

  3/15/24 → 3/15/27

  Project: Research project

• A Functional Genomics Platform for the de novo Identification of Disease-relevant Alleles

  Hultquist, J. F. (PD/PI)

  National Center for Advancing Translational Sciences

  3/15/24 → 3/31/26

  Project: Research project

• Prot #M24-427: A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications

  Mahalingam, D. (PD/PI)

  Parexel, AbbVie Inc.

  3/13/24 → 3/13/27

  Project: Research project

• Prot #GB002-3101: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)

  Mylvaganam, R. J. (PD/PI)

  PPD Investigator Services, LLC, GB002, Inc.

  3/12/24 → 3/12/27

  Project: Research project

• Prot #KO-MEN-007: Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib (KO-539) or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloi

  Altman, J. K. (PD/PI)

  Quintiles, Inc., Kura Oncology, Inc.

  3/12/24 → 3/12/27

  Project: Research project

• Northwestern University CoFAR (NU-CoFAR) Clinical Research Center

  Gupta, R. S. (PD/PI), Berin, C. (Co-PD/PI), Eisenbarth, S. C. (Co-Investigator) & Williams, A. J. (Co-Investigator)

  National Institute of Allergy and Infectious Diseases

  3/11/24 → 2/28/31

  Project: Research project

• Prot #Vedolizumab-4052: Re-define the IBD disease burden status

  Dulai, P. S. (PD/PI)

  Takeda Pharmaceuticals U.S.A., Inc.

  3/11/24 → 3/11/27

  Project: Research project

• Modulation and exploitation of Siglec-6 function to broadly impede mast cell activation

  O'Sullivan, J. A. (PD/PI) & Bochner, B. S. (Other)

  National Institute of Allergy and Infectious Diseases

  3/7/24 → 1/31/29

  Project: Research project

• Prot #ATYR1923-C-005: Randomized, Double-Blind, Placebo-Controlled Proof-ofConcept Study to Evaluate the Efficacy, Safety and Tolerability of Efzofitimod in Patients With Systemic Sclerosis Related Interstitial Lung Disease

  Bemiss, B. (PD/PI)

  aTyr Pharma, Inc.

  3/7/24 → 3/7/27

  Project: Research project

• Covid-19 transmission, testing, and vaccination dynamics within migrant worker social networks

  Kandula, N. R. (PD/PI)

  The University of Chicago, National Institute of Allergy and Infectious Diseases

  3/5/24 → 1/31/26

  Project: Research project

• Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal medicines for Heart Failure with reduced ejection fraction: I-I-CAPTAIN

  Ahmad, F. S. (PD/PI), Ahmad, F. S. (PD/PI), Sweis, R. N. (Co-Investigator) & Sweis, R. N. (Co-Investigator)

  University of Colorado Denver, Patient-Centered Outcomes Research Institute

  3/1/24 → 3/1/29

  Project: Research project

• Gut microbiota metabolite sensing licenses IEC to cross talk with T cells to inhibit intestinal inflammation

  Cong, Y. (PD/PI), Yang, W. (Other), Yao, S. (Other) & Yu, T. (Other)

  National Institute of Diabetes and Digestive and Kidney Diseases

  3/1/24 → 1/31/27

  Project: Research project

• Prot #20210004: A Randomized, Open-Label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-Based First-Line Chemotherapy (DeLLphi-304)

  Patel, J. D. (PD/PI)

  Amgen, Inc.

  2/29/24 → 2/28/27

  Project: Research project

• Prot #STU00220812: FDA-AF Study: Fibricheck Detection cApabilities for Atrial Fibrillation - A Multicenter Validation Study

  Thomas, J. D. (PD/PI)

  Qompium NV

  2/28/24 → 2/28/27

  Project: Research project

• Prot #TVTX-RE021-204: A Multicentered, Single-Group Phase 2, Exploratory, OpenLabel Study to Investigate Safety and Effect of Sparsentan in Combination with Sodium Glucose Cotransporter-2 (SGLT2) Inhibition in the Treatment of Adult Participants with Immu

  Wadhwani, S. (PD/PI)

  George Clinical Pty Ltd., Retrophin, Inc.

  2/27/24 → 2/27/27

  Project: Research project

• Novel Imaging approach for noninvasive and longitudinal monitoring of GBM responses to Immunotherapy

  Balyasnikova, I. V. (PD/PI), Procissi, D. (Co-Investigator) & Zhao, M. (Co-Investigator)

  Charlie Teo Foundation

  2/26/24 → 2/25/26

  Project: Research project